Navigation Links
Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO

IRVINE, Calif., April 15, 2011 /PRNewswire/ -- Shrink Nanotechnologies, Inc. ("Shrink") (OTCBB:INKN), an innovative high technology company announced today that critical intellectual property for Shrink's Cell Align™ cell culturing and tissue engineering material, along with a novel higher performing immunoassay substrate has been filed with the US Patent & Trademark Office.

Cell Align is a micro-fabricated substrate with non-periodic (or random) linear patterned grooves that allow for the alignment of cells along a single axis. The unique design is ideal for growing biological tissues from stem cells, especially those that naturally grow in a linear fashion such as in cardiac and nerve tissues.

Shrink CEO Mark L. Baum stated, "Our team is pleased with the recent filings for our Cell Align product portfolio, as well as the filing made for our novel immunoassay substrate.  These filings mean that, from an intellectual property perspective, we are able to move into multiple versions of, for example, the Cell Align product, using a scalable manufacturing process and a material that performs better than materials we formerly worked with.  As we plan our go-to-market strategy for Cell Align, because of this new IP, the materials we use and the manufacturing process we employ will deliver a better product to end-users, and from our shareholders' perspective, they deliver better value and profit potential."

"A large potential market for our new patent-pending material is as a substrate in immunoassays.  Shrink has been working in this space for two years, and we believe that the materials we are now working with perform better than any that we have used in the past.  Historically we have been able to show results that exceeded key parameters in performance, relative to existing immunoassay substrates.  Our objective is always to go head-to-head with existing market leading platforms and show that we are able to reduce the problematic 'noise' while maintaining a high signal.  We will continue to optimize our new patent pending material, and conduct additional tests, working towards collaborations and licensing opportunities with market leading immunoassay companies."

In the United States, tissue engineering and cell therapy comprised a $6.9 billion market for regenerative products in 2009, and is expected to approach $32 Billion by 2018, according to the 2010 MedMarket Diligence's Report, "Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018."  The report says the market for cellular therapies may benefit many disorders, including degenerative and traumatic orthopedic and spine injuries, cardiac and vascular disease, neurological disorders, diabetes, inflammatory diseases, and tooth decay.

About Shrink Nanotechnologies, Inc.

Shrink Nanotechnologies, Inc. is a FIGA™ organization, focusing on leveraging contributions from experts in Finance, Industry, Government and Academia. Operating as a high-technology development-stage company, Shrink licenses, owns and in all cases develops proprietary and patent-pending nano-sized technologies, components and product systems for a number of leading edge technology markets of varying sizes. For more information, please visit

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release due to a myriad of factors given the stage of development of Shrink. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Shrink is a development stage company and any investment in Shrink should only be made after (i) review of our public filings with the U.S. Securities and Exchange Commission (, particularly the "Risk Factors" in our most recent Form 10-K, and (ii) after counsel from a registered investment professional.


For Shrink Nanotechnologies
Mark L. Baum


SOURCE Shrink Nanotechnologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells
2. Seniors Shortchanged on Time as Annual Enrollment Period Shrinks This Fall
3. Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas
4. New Cancer Treatment Shrinks Pancreatic Tumor
5. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
6. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
7. To Reach, Perchance to Kill the Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That Sea of Troubles
8. Tongjitang Chinese Medicines Company Announces Closing of Merger and Intent to Delist from the NYSE
9. ULURU Inc. Announces Commercial Exhibit and Scientific Presentations at the SAWC/WHS National Wound Symposium
10. LifeVantage Announces Preliminary Third Quarter 2011 Revenue
11. Beacon Announces Agreement With New Fortune 500 Pharmaceutical Client
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... Health-E-minds, an innovative online platform for mental health and wellness consultation, has collaborated ... This partnership will bridge the knowledge gap experienced by parents and bring advice ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Dr. Thomas ... Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph ... that both STEMI and Sepsis conditions present in similar ways and require time-critical intervention ...
Breaking Medicine News(10 mins):